Don't Miss The World's #1 Executive Networking Event"
The story behind the story.
The $4 Question: Can Curaleaf Convince Aurora Shareholders to Sell?
Aurora tells shareholders to reject, Rolando García does the math, and Glass House rings the NYSE bell.
Hi friends, this is Nico Rodriguez, Managing Editor at IgniteIt.
The Curaleaf–Aurora fight entered a new phase this week. Aurora formally told shareholders to reject the offer, Curaleaf fired back, and the debate is increasingly shifting from whether the deal makes strategic sense to whether Curaleaf can actually convince enough shareholders to tender at $4.
That question is at the center of the first column from our new Chief Economic Columnist, Rolando García, who looks beyond the increasingly aggressive rhetoric to examine the mechanics of the hostile bid — and an unusual problem Boris Jordan may have created for himself by arguing that Aurora could be worth considerably more in Curaleaf’s hands.
There are other signs that cannabis capital markets are moving. Glass House rang the NYSE bell, Ascend took another step toward a potential major-exchange listing, and Decibel completed a 15-for-1 share consolidation as it considers its own path to a senior TSX listing. Meanwhile, Congress has bought the hemp industry a little more time, but not much.
Let’s get into the stories shaping the cannabis business this week.
IgniteIt’s Top Stories
Curaleaf–Aurora Enters a New Phase
The fight over Curaleaf’s proposed acquisition of Aurora Cannabis escalated this week, with both sides sharpening their arguments over what Aurora is worth — and what shareholders would actually own if the deal goes through.
Aurora has now formally recommended that shareholders reject Curaleaf’s offer, arguing that the proposal undervalues a debt-free company with approximately $149 million in cash and a growing international medical cannabis business. Aurora also targeted Curaleaf’s debt, tax liabilities and dual-class share structure, arguing that Aurora shareholders would receive roughly 7.7% of the combined company’s equity but only 3.2% of its voting power.
Curaleaf answered almost immediately. The company continues to defend its 45% headline premium and argues that Aurora’s debt-free balance sheet came at a high cost to shareholders through equity issuance. Curaleaf says Aurora has raised approximately $398 million through dilutive equity issuances since September 2020, while citing its own $145 million in trailing 12-month operating cash flow as evidence that its leverage should be viewed in the context of a much larger cash-generating business.
→Aurora Urges Shareholders to Reject Curaleaf Offer, Citing Cash, Debt and Voting Rights →Curaleaf Escalates Aurora Takeover Fight, Attacks Dilution, Cash Burn and Six-Year Turnaround
The Math Behind the Hostile Bid
The rhetoric is getting sharper, but underneath the attacks on debt, dilution, cash flow and management records sits a more basic question: can Curaleaf actually persuade enough Aurora shareholders to tender their shares?
García argues that Curaleaf may have created an unusual problem for itself. Boris Jordan’s pitch is fundamentally that Aurora owns valuable assets that are not being used efficiently — and that Curaleaf could generate substantially more value from them. But the more persuasive that argument becomes, the easier it may be for an Aurora shareholder to conclude that $4 per share isn’t enough.
Aurora’s dispersed shareholder base makes that problem particularly important. García breaks the takeover down into three numbers: 50%, 66⅔% and 90%. Curaleaf needs more than 50% of the independent shares tendered before it can take up any shares. It has imposed its own 66⅔% minimum-deposit condition, although that can be waived. Reaching 90% would open the door to compulsory acquisition of the remaining shares.
And the market has already moved in an interesting direction. Aurora went from trading at a 5.3% discount to the implied consideration to slightly above the offer in just 14 sessions. García doesn’t argue that this guarantees a higher bid. Rather, he sees the disappearing merger spread as evidence that expectations around the transaction have changed.
His piece ultimately makes the takeover battle testable. Curaleaf may clear the statutory 50% threshold. Getting to 66⅔% could prove harder. If enough Aurora shareholders decide to wait, Curaleaf could eventually face a choice between waiving its own condition, extending the offer, or improving the terms.
In other words, Aurora says it is worth more. Curaleaf says Aurora’s record proves otherwise.
Hemp Update: Congress Moves to Delay the Federal THC Crackdown
AJ Herrington spoke with U.S. Hemp Roundtable general counsel Jonathan Miller, Cornbread Hemp co-founder Jim Higdon and U.S. Cannabis Roundtable’s David Mangone about what the one-month reprieve actually means — and whether Congress can find a path forward for intoxicating hemp before the new deadline. Their answers reveal just how far apart the industry remains.
Road to the U.S. Listings
Glass House Brands rang the NYSE Closing Bell on Aug. 28, nearly two months after its shares began trading under GLAS. The milestone followed a restructuring of its California retail operations and has expanded its financing options, including an updated $100 million at-the-market equity program. Adviser, investor and shareholder Seth Yakatan told IgniteIt that Glass House could benefit significantly if U.S.-grown medical cannabis eventually reaches international markets.
Meanwhile, this week Ascend Wellness shareholders approved a 1-for-10 to 1-for-50 reverse stock split, giving the company a path toward meeting NYSE or Nasdaq share-price requirements, although an uplisting is not guaranteed.
Upcoming IgniteIt Events
The Bottom Line
This week’s stories point to a cannabis capital market that is starting to move again, but on very different tracks. Curaleaf–Aurora is testing whether scale and international infrastructure justify a major hostile acquisition, while Glass House and Ascend are pursuing better access to the U.S. And the hemp fight shows how quickly federal policy can still redraw the economics of an entire category.
For investors, the common thread is execution. A listing, reverse split, acquisition or regulatory change doesn’t create value on its own. What matters is what management does with the access to capital, assets and opportunities those moves provide — and whether shareholders ultimately participate in the value created.
Nico Rodriguez
Managing Editor, IgniteIt
Before You Go
Decibel Shrinks Its Share Count — Why Should Investors Care?
Decibel Cannabis has completed a 15-for-1 share consolidation, cutting its outstanding shares from roughly 577 million to 38.47 million. The move doesn’t dilute shareholders or change the company’s underlying value by itself. The more interesting question is why now: Decibel is considering a share buyback and a potential move from the TSX Venture Exchange to the senior TSX just as revenue, EBITDA, free cash flow and international sales are growing.
Our analysis digs into the post-split float and fully diluted share count, the potential uplisting, Decibel’s rapidly expanding international business, and what analyst Pablo Zuanic’s forecasts imply for its valuation.
$10 Million in Taxpayer Money Was Diverted Into Florida’s Fight Against Marijuana Legalization, Grand Jury Says
A Florida grand jury has concluded that $10 million in taxpayer money was misappropriated, with $8.5 million ultimately reaching a political committee that helped defeat Amendment 3, Florida’s 2024 adult-use cannabis initiative.
The grand jury found insufficient evidence to bring criminal charges, but its findings reopen a much bigger question about one of the most expensive cannabis legalization fights in the country: where the money opposing legalization actually came from.